- Home
- EBTC vs TRML Comparison
EBTC vs TRML Comparison
Compare EBTC & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBTC
- TRML
- Stock Information
- Founded
- EBTC 1989
- TRML 2021
- Country
- EBTC United States
- TRML United States
- Employees
- EBTC N/A
- TRML N/A
- Industry
- EBTC Major Banks
- TRML Biotechnology: Pharmaceutical Preparations
- Sector
- EBTC Finance
- TRML Health Care
- Exchange
- EBTC Nasdaq
- TRML Nasdaq
- Market Cap
- EBTC 455.5M
- TRML 419.1M
- IPO Year
- EBTC 2005
- TRML N/A
- Fundamental
- Price
- EBTC $41.72
- TRML $19.93
- Analyst Decision
- EBTC
- TRML Strong Buy
- Analyst Count
- EBTC 0
- TRML 6
- Target Price
- EBTC N/A
- TRML $54.00
- AVG Volume (30 Days)
- EBTC 50.1K
- TRML 179.5K
- Earning Date
- EBTC 01-23-2025
- TRML 11-07-2024
- Dividend Yield
- EBTC 2.21%
- TRML N/A
- EPS Growth
- EBTC N/A
- TRML N/A
- EPS
- EBTC 2.91
- TRML N/A
- Revenue
- EBTC $164,115,000.00
- TRML N/A
- Revenue This Year
- EBTC N/A
- TRML N/A
- Revenue Next Year
- EBTC N/A
- TRML N/A
- P/E Ratio
- EBTC $14.94
- TRML N/A
- Revenue Growth
- EBTC N/A
- TRML N/A
- 52 Week Low
- EBTC $22.60
- TRML $12.12
- 52 Week High
- EBTC $44.08
- TRML $48.31
- Technical
- Relative Strength Index (RSI)
- EBTC 68.09
- TRML 37.20
- Support Level
- EBTC $42.13
- TRML $21.20
- Resistance Level
- EBTC $43.48
- TRML $22.80
- Average True Range (ATR)
- EBTC 1.24
- TRML 1.56
- MACD
- EBTC 0.30
- TRML -0.33
- Stochastic Oscillator
- EBTC 83.61
- TRML 8.08
About EBTC Enterprise Bancorp Inc
Enterprise Bancorp Inc is a holding company engaged in the business of gathering deposits from the general public and investing in loans and investment securities. Through the Bank and its subsidiaries, the company offers a range of commercial, residential, and consumer loan products, deposit products, and cash management services, as well as wealth management and wealth services.
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.